Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EIK1004-001 (IMP1707-001)
EIK1004-001 · 1 trial · 1 indication
A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). The number of participants who experience a DLT will be reported.
Number of participants reporting adverse events or serious adverse events which include any abnormal clinical events, laboratory assessments outside of normal clinical range, abnormal vital signs observed, and any abnormal ECG parameters
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | EIK1004 (IMP1707) monotherapy; oral tablet(s) daily (except for the single-dose period). Participants will receive escalating doses of EIK1004 (IMP1707) until progressive disease or discontinuation. |
| Name | Type | Description |
|---|---|---|
| EIK1004-001 (IMP1707-001) | DRUG | PARP1 selective inhibitor |
• Breast cancer: must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+, HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemothe...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
EIK1004-001 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in a clinical trial enrolling participants with advanced solid tumors.
EIK1004-001 targets PARP1, a protein involved in DNA repair. By inhibiting PARP1, the drug is designed to interfere with cancer cell survival mechanisms. This targeted approach is being evaluated in a Phase 1 clinical trial for advanced solid tumors.
EIK1004-001 is being developed by Eikon Therapeutics, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial of the drug in participants with advanced solid tumors. Eikon Therapeutics is publicly traded under the ticker symbol EIKN.
EIK1004-001 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is recruiting participants with advanced solid tumors to evaluate the drug's safety and tolerability.
EIK1004-001 is being studied in one active Phase 1 clinical trial with the identifier NCT06907043. This trial is titled 'A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors' and is recruiting participants in the United States, Australia, and China.
Yes, EIK1004-001 is also known as IMP1707-001. The drug is referred to by both names in clinical development. The ongoing Phase 1 trial NCT06907043 uses the name EIK1004 (IMP1707) to describe the investigational PARP1 inhibitor.